Ahmedabad-based Sun Pharma today announced that it received an approval from US Food and Drug Administration to market a generic version of anti-depressant Venlafaxine Hydrochloride Extended Release Tablets.
The generic tablets of Sun Pharma are equivalent therapeutically to Osmotica's Venlafaxine Hydrochloride, in three strengths. This drug has been indicated for the management of major depressive disorders. The product is expected to hit the market shortly.
Sun Pharma has interests in branded generics as well as generics, in India, US and several markets. In India, the company has a good presence in therapy areas like psychiatry, neurology, cardiology, diabetology, gastroenterology, orthopedics and opthalmology.